Vaping Likely Causes Lung and Oral Cancer: What the June 2026 Review Means for Americans
For years, the vaping industry marketed e-cigarettes as a safer alternative to smoking. Millions of Americans — including alarming numbers of teenagers — adopted vaping believing they were avoiding the harms of tobacco. A major review published on June 21, 2026 has definitively challenged that assumption: nicotine vapes are likely to cause lung and oral cancers, researchers concluded after analyzing evidence ranging from human biomarkers to animal and laboratory studies.
As a pharmacist with 40 years of clinical experience watching tobacco harm and now the vaping epidemic unfold, this finding is not surprising — but it is urgent. Approximately 4.5% of American adults currently vape, with usage dramatically higher among young adults (18-24) at over 11%. The public health implications of this research demand immediate attention.
The June 2026 Review: What It Found
The comprehensive review analyzed multiple lines of evidence, including human biomarker studies (measuring carcinogen exposure and DNA damage in vapers), animal inhalation studies, and cell culture laboratory studies. The researchers concluded that nicotine vapes are “likely to cause” lung and oral cancers — language used when biological plausibility is established and evidence is accumulating but long-term human epidemiological data is still maturing.
Key findings from the evidence base:
- Vapers show elevated levels of known carcinogens in their urine and blood — including acrolein, formaldehyde, and acrylamide — at levels significantly above non-vapers
- Vaping aerosol contains hundreds of chemicals including aldehydes, heavy metals (nickel, tin, lead), and ultrafine particles that penetrate deep into lung tissue
- DNA damage markers in oral and lung tissue of vapers are significantly elevated compared to non-users
- Long-term mouse inhalation studies show lung tumor development from chronic vaping exposure
- Flavoring chemicals used in vaping liquids — including diacetyl and cinnamaldehyde — cause significant airway inflammation and cell damage
Why “Safer Than Cigarettes” Was Never “Safe”
The “safer than cigarettes” claim deserves context. Combustible cigarettes are extraordinarily carcinogenic — they deliver carbon monoxide, tar, and hundreds of carcinogens from burning tobacco. Vaping avoids combustion — which is a genuine harm reduction for established smokers who cannot quit.
But “safer than the most harmful consumer product in history” is an extremely low bar. The 2026 review’s finding that vaping likely causes lung and oral cancers means:
- For non-smokers who vape, there is no safe exposure level — they are taking on cancer risk for zero benefit
- For teen and young adult vapers, long-term cancer risk accumulates from an age when lung cancer would otherwise be extremely rare
- The “harm reduction” framing has been weaponized to recruit never-smokers into nicotine addiction
Beyond Cancer: The Full Vaping Health Risk Profile
EVALI — Vaping-Associated Lung Injury
In 2019, a nationwide outbreak of EVALI (e-cigarette or vaping product use-associated lung injury) hospitalized over 2,800 Americans and killed at least 68. The primary culprit was vitamin E acetate used as a thickener in THC vaping cartridges — but the outbreak revealed the acute lung injury potential of inhaled vaping aerosols.
Cardiovascular Effects
Nicotine — regardless of delivery method — increases heart rate, raises blood pressure, constricts blood vessels, and promotes platelet aggregation. Vaping delivers nicotine at concentrations often higher than cigarettes (particularly JUUL and similar salt nicotine products). Vaping is not cardiovascular-neutral.
Nicotine Addiction in Young Americans
This is perhaps the most damaging outcome of the vaping epidemic. Teen nicotine addiction rates — which had been declining steadily for decades as cigarette smoking declined — reversed sharply with vaping adoption. The adolescent brain is particularly susceptible to nicotine addiction, and early nicotine exposure during brain development has lasting effects on dopamine circuitry, attention, and impulse control.
Respiratory Disease
Chronic respiratory symptoms — coughing, wheezing, shortness of breath — are more prevalent in vapers than non-users. Popcorn lung (bronchiolitis obliterans) from diacetyl exposure, a flavoring chemical in many vaping liquids, represents a severe and irreversible airway disease documented in vapers.
The Teen Vaping Crisis — An American Emergency
While adult vaping prevalence has stabilized, the youth vaping crisis remains severe. Despite FDA restrictions on flavored cartridges, disposable vapes with thousands of flavor options remain accessible to teens. The CDC’s 2025 Youth Risk Behavior Survey found that approximately 1 in 10 high school students currently vapes — representing approximately 1.6 million American teenagers actively addicted to nicotine at a stage when their brains are most vulnerable to its effects.
Parents should know the signs of teen vaping: unusual sweet or fruity smells, increased thirst (propylene glycol in vaping liquid causes mouth dryness), unfamiliar USB-like devices or pods, mood changes consistent with nicotine craving/withdrawal, and nosebleeds (from vaping-induced mucous membrane dryness).
For Smokers Who Vape to Quit: The Pharmacist’s Perspective
The calculus is different for established cigarette smokers using vaping as a cessation tool. Combustible cigarette smoking kills approximately 480,000 Americans annually — vaping is almost certainly less acutely harmful than continued smoking. For a pack-a-day smoker who cannot quit through other means, transitioning to vaping while pursuing complete nicotine cessation is a reasonable harm reduction step.
But the goal must be complete cessation — not indefinite vaping. Evidence-based cessation tools that should be used alongside or instead of vaping:
- Varenicline (Chantix/Champix): Most effective pharmacological cessation agent — doubles quit rates versus placebo. FDA safety concerns have been largely resolved with the revised labeling.
- Bupropion (Zyban/Wellbutrin): Antidepressant with nicotine cessation efficacy; particularly useful for smokers with concurrent depression
- Nicotine replacement therapy (NRT): Patch, gum, lozenge, inhaler, nasal spray — combination NRT (patch + short-acting form) is most effective
- Behavioral support: Counseling significantly improves quit rates; 1-800-QUIT-NOW (1-800-784-8669) provides free coaching
- Combination therapy: Varenicline + NRT + behavioral support produces the highest quit rates
The Bottom Line
The June 2026 review removes any remaining justification for treating vaping as benign. It likely causes lung and oral cancers. It delivers addictive nicotine — often at high concentrations. It harms cardiovascular health. And it has created a new generation of nicotine-addicted American teenagers.
After 40 years of pharmacy practice watching nicotine’s devastation, my message is clear: if you don’t smoke or vape, don’t start. If you vape and don’t smoke cigarettes, stop — you are taking on cancer risk with no benefit. If you smoke and use vaping to transition to quitting, pursue complete cessation with the proven tools above. The goal is zero nicotine, through whatever path gets you there.
Disclaimer: Our content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. For smoking or vaping cessation support, consult your physician or pharmacist. Call 1-800-QUIT-NOW for free cessation coaching. Always seek the advice of your healthcare provider.
